The antagonist of P2Y11 receptor NF157 ameliorates oxidized LDL-induced vascular endothelial inflammation

References

• Anggård EE. The endothelium-the body's largest endocrine gland? J Endocrinol. 1990;127:371–375.
   PubMed Web of Science ®Google Scholar
• Gimbrone MA, Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620–636.
   PubMed Web of Science ®Google Scholar
• Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924.
   PubMed Web of Science ®Google Scholar
• Di Pietro N, Formoso G, Pandolfi A. Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascul Pharmacol. 2016;84:1–7.
   PubMed Web of Science ®Google Scholar
• Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413–492.
   PubMed Web of Science ®Google Scholar
• Burnstock G, Ralevic V. Purinergic signaling and blood vessels in health and disease. Pharmacol Rev. 2014;66:102–192.
   PubMed Web of Science ®Google Scholar
• Umapathy NS, Zemskov EA, Gonzales J, et al. Extracellular beta-nicotinamide adenine dinucleotide (beta-NAD) promotes the endothelial cell barrier integrity via PKA- and EPAC1/Rac1-dependent actin cytoskeleton rearrangement. J Cell Physiol. 2010;223:215–223.
   PubMed Web of Science ®Google Scholar
• Zhou X, Cai J, Liu W, et al. Cysteinyl leukotriene receptor type 1 (CysLT1R) antagonist zafirlukast protects against TNF-α-induced endothelial inflammation. Biomed Pharmacother. 2019;111:452–459.
   PubMed Web of Science ®Google Scholar
• Ma S, Bai Z, Wu H, et al. The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB. Eur J Pharmacol. 2019;851:186–193.
   PubMed Web of Science ®Google Scholar
• Khalid M, Brisson L, Tariq M, et al. Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells. Oncotarget. 2017;8:37278–37290.
   PubMedGoogle Scholar
• Sakaki H, Tsukimoto M, Harada H, et al. Autocrine regulation of macrophage activation via exocytosis of ATP and activation of P2Y11 receptor. PLoS One. 2013;8:e59778.
   PubMed Web of Science ®Google Scholar
• Communi D, Govaerts C, Parmentier M, et al. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem. 1997;272:31969–31973.
   PubMed Web of Science ®Google Scholar
• Wang L, Karlsson L, Moses S, et al. P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol. 2002;40:841–853.
   PubMed Web of Science ®Google Scholar
• Dreisig K, Kornum BR. A critical look at the function of the P2Y11 receptor. Purinergic Signal. 2016;12:427–437.
   PubMed Web of Science ®Google Scholar
• Liu C, Mather S, Huang Y, et al. Extracellular ATP facilitates flow-induced vasodilatation in rat small mesenteric arteries. Am J Physiol Heart Circ Physiol. 2004;286:H1688–H1695.
   PubMed Web of Science ®Google Scholar
• Zemskov E, Lucas R, Verin AD, et al. P2Y receptors as regulators of lung endothelial barrier integrity. J Cardiovasc Dis Res. 2011;2:14–22.
   PubMedGoogle Scholar
• Xiao Z, Yang M, Lv Q, et al. P2Y11 impairs cell proliferation by induction of cell cycle arrest and sensitizes endothelial cells to cisplatin-induced cell death. J Cell Biochem. 2011;112:2257–2265.
   PubMed Web of Science ®Google Scholar
• Helenius MH, Vattulainen S, Orcholski M, et al. Suppression of endothelial CD39/ENTPD1 is associated with pulmonary vascular remodeling in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2015;308:L1046–L1057.
   PubMed Web of Science ®Google Scholar
• Moreschi I, Bruzzone S, Nicholas RA, et al. Extracellular NAD + is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J Biol Chem. 2006;281:31419–31429.
   PubMed Web of Science ®Google Scholar
• Ullmann H, Meis S, Hongwiset D, et al. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem. 2005;48:7040–7048.
   PubMed Web of Science ®Google Scholar
• Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Atvb. 2007;27:2292–22301.
   Web of Science ®Google Scholar
• Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107:1255–1262.
   PubMed Web of Science ®Google Scholar
• Ago T, Kitazono T, Ooboshi H, et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 2004; 109:227–233.
   PubMed Web of Science ®Google Scholar
• Pirillo A, Reduzzi A, Ferri N, et al. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. Atherosclerosis. 2011; 214:331–337.
   PubMed Web of Science ®Google Scholar